Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study
IntroductionThe relationship between immune-related thyroid dysfunction (irTD) and survival rates in cancer patients remains unclear. Furthermore, the impact of variations in immunotherapy line numbers and pathological types among lung cancer patients on this relationship has not been fully elucidat...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1495460/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846111689226846208 |
|---|---|
| author | Ge Guo Zihan Jing Wenrui Dou Guiqin Wang JunJie Dang Yajie Li Ruqiong Wang Huan Zhang Jing Sun Lihua Shang |
| author_facet | Ge Guo Zihan Jing Wenrui Dou Guiqin Wang JunJie Dang Yajie Li Ruqiong Wang Huan Zhang Jing Sun Lihua Shang |
| author_sort | Ge Guo |
| collection | DOAJ |
| description | IntroductionThe relationship between immune-related thyroid dysfunction (irTD) and survival rates in cancer patients remains unclear. Furthermore, the impact of variations in immunotherapy line numbers and pathological types among lung cancer patients on this relationship has not been fully elucidated. This study aims to evaluate the potential of irTD as a prognostic marker for immunotherapy in Chinese patients with lung cancer.MethodsA retrospective analysis was conducted on data collected from patients with locally advanced or metastatic lung cancer who received immune checkpoint inhibitor treatment at the Harbin Medical University Cancer Hospital. The study period spanned from December 1, 2016, to November 30, 2023. The primary endpoints were progression-free survival (PFS) and overall survival (OS), while the objective response rate served as the secondary endpoint.ResultsAmong the 361 patients in this study, 42.7% developed irTD. Significant differences were observed between the groups with and without irTD regarding inflammatory indices, thyroid-stimulating hormone levels, and thyroid autoantibody positivity (P < 0.05). Patients with irTD demonstrated longer OS (32.5 vs. 22 months, HR: 0.65, 95% CI: 0.49-0.88; P = 0.005). For NSCLC patients, OS was significantly prolonged in those with irTD (40.8 vs. 27.2 months, HR: 0.68, 95% CI: 0.48-0.96; P = 0.028). Similarly, SCLC patients who developed irTD exhibited longer OS (27.9 vs. 13.8 months, HR: 0.51, 95% CI: 0.29-0.90; P = 0.022). Notably, irTD was observed exclusively in patients receiving immunotherapy in the second or later lines, showing a significant association with extended OS (40.8 vs. 19.4 months, HR: 0.56, 95% CI: 0.35-0.88; P = 0.012), while the presence of irTD during first-line immunotherapy did not confer a benefit to patients (32.4 vs 24.5 months, HR: 0.74, 95% CI: 0.50-1.10; P = 0.134). The effects of different irTD types, severities, or clinical symptoms on PFS and OS did not differ significantly (P > 0.05).ConclusionirTD demonstrates potential as a predictive marker for long-term survival benefits in Chinese patients with lung cancer. However, our exploratory analysis indicates that this association was exclusively observed in individuals receiving immunotherapy as a second-line or subsequent treatment. |
| format | Article |
| id | doaj-art-6080a12e398e4df7bb11f3fbfd8473bf |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-6080a12e398e4df7bb11f3fbfd8473bf2024-12-23T06:38:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-12-011510.3389/fimmu.2024.14954601495460Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective studyGe Guo0Zihan Jing1Wenrui Dou2Guiqin Wang3JunJie Dang4Yajie Li5Ruqiong Wang6Huan Zhang7Jing Sun8Lihua Shang9Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, ChinaDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, ChinaDepartment of Clinical Medicine, Harbin Medical University, Harbin, ChinaSchool of Marxism, Sanquan College of Xinxiang Medical University, Xinxiang, ChinaDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, ChinaDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, ChinaDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, ChinaDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, ChinaDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, ChinaDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, ChinaIntroductionThe relationship between immune-related thyroid dysfunction (irTD) and survival rates in cancer patients remains unclear. Furthermore, the impact of variations in immunotherapy line numbers and pathological types among lung cancer patients on this relationship has not been fully elucidated. This study aims to evaluate the potential of irTD as a prognostic marker for immunotherapy in Chinese patients with lung cancer.MethodsA retrospective analysis was conducted on data collected from patients with locally advanced or metastatic lung cancer who received immune checkpoint inhibitor treatment at the Harbin Medical University Cancer Hospital. The study period spanned from December 1, 2016, to November 30, 2023. The primary endpoints were progression-free survival (PFS) and overall survival (OS), while the objective response rate served as the secondary endpoint.ResultsAmong the 361 patients in this study, 42.7% developed irTD. Significant differences were observed between the groups with and without irTD regarding inflammatory indices, thyroid-stimulating hormone levels, and thyroid autoantibody positivity (P < 0.05). Patients with irTD demonstrated longer OS (32.5 vs. 22 months, HR: 0.65, 95% CI: 0.49-0.88; P = 0.005). For NSCLC patients, OS was significantly prolonged in those with irTD (40.8 vs. 27.2 months, HR: 0.68, 95% CI: 0.48-0.96; P = 0.028). Similarly, SCLC patients who developed irTD exhibited longer OS (27.9 vs. 13.8 months, HR: 0.51, 95% CI: 0.29-0.90; P = 0.022). Notably, irTD was observed exclusively in patients receiving immunotherapy in the second or later lines, showing a significant association with extended OS (40.8 vs. 19.4 months, HR: 0.56, 95% CI: 0.35-0.88; P = 0.012), while the presence of irTD during first-line immunotherapy did not confer a benefit to patients (32.4 vs 24.5 months, HR: 0.74, 95% CI: 0.50-1.10; P = 0.134). The effects of different irTD types, severities, or clinical symptoms on PFS and OS did not differ significantly (P > 0.05).ConclusionirTD demonstrates potential as a predictive marker for long-term survival benefits in Chinese patients with lung cancer. However, our exploratory analysis indicates that this association was exclusively observed in individuals receiving immunotherapy as a second-line or subsequent treatment.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1495460/fulllung neoplasmsimmune checkpoint inhibitorirAEsimmune-related thyroid dysfunctionprediction biomarker |
| spellingShingle | Ge Guo Zihan Jing Wenrui Dou Guiqin Wang JunJie Dang Yajie Li Ruqiong Wang Huan Zhang Jing Sun Lihua Shang Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study Frontiers in Immunology lung neoplasms immune checkpoint inhibitor irAEs immune-related thyroid dysfunction prediction biomarker |
| title | Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study |
| title_full | Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study |
| title_fullStr | Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study |
| title_full_unstemmed | Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study |
| title_short | Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study |
| title_sort | immune related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in china a real world retrospective study |
| topic | lung neoplasms immune checkpoint inhibitor irAEs immune-related thyroid dysfunction prediction biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1495460/full |
| work_keys_str_mv | AT geguo immunerelatedthyroiddysfunctionasapositiveprognosticfactorforpatientswithlungcancerinchinaarealworldretrospectivestudy AT zihanjing immunerelatedthyroiddysfunctionasapositiveprognosticfactorforpatientswithlungcancerinchinaarealworldretrospectivestudy AT wenruidou immunerelatedthyroiddysfunctionasapositiveprognosticfactorforpatientswithlungcancerinchinaarealworldretrospectivestudy AT guiqinwang immunerelatedthyroiddysfunctionasapositiveprognosticfactorforpatientswithlungcancerinchinaarealworldretrospectivestudy AT junjiedang immunerelatedthyroiddysfunctionasapositiveprognosticfactorforpatientswithlungcancerinchinaarealworldretrospectivestudy AT yajieli immunerelatedthyroiddysfunctionasapositiveprognosticfactorforpatientswithlungcancerinchinaarealworldretrospectivestudy AT ruqiongwang immunerelatedthyroiddysfunctionasapositiveprognosticfactorforpatientswithlungcancerinchinaarealworldretrospectivestudy AT huanzhang immunerelatedthyroiddysfunctionasapositiveprognosticfactorforpatientswithlungcancerinchinaarealworldretrospectivestudy AT jingsun immunerelatedthyroiddysfunctionasapositiveprognosticfactorforpatientswithlungcancerinchinaarealworldretrospectivestudy AT lihuashang immunerelatedthyroiddysfunctionasapositiveprognosticfactorforpatientswithlungcancerinchinaarealworldretrospectivestudy |